Technical Analysis for ALRN - Aileron Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 0.00% | |
| Outside Day | Range Expansion | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Earnings Movers | Other | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Up 3 Days in a Row | Strength | 0.00% | |
| Up 4 Days in a Row | Strength | 0.00% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 0.52% | |
| Narrow Range Bar | Range Contraction | 0.52% |
| Alert | Time |
|---|---|
| 10 DMA Support | about 18 hours ago |
| Outside Day | about 19 hours ago |
| Down 5% | about 19 hours ago |
| Down 3% | about 19 hours ago |
| Fell Below Previous Day's Low | about 19 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 05/13/2024
Aileron Therapeutics, Inc. Description
Aileron Therapeutics, Inc. is a United States-based clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing a class of therapeutics called stapled peptides. It is also developing a pipeline of stapled peptide drugs across a range of therapeutic areas, including cancer, endocrine and metabolic diseases and inflammation. The Company is advancing its lead oncology program to deliver efficacy and safety in a spectrum of solid and hematological malignancies. Its lead product candidate, ALRN-6924, targets the tumor suppressor protein p53 for the treatment of a range of cancers. The Company is conducting an ongoing Phase I clinical trial of ALRN-6924 in adult patients with solid tumors or lymphomas expressing non-mutated or wild-type p53 that are refractory to or intolerant of standard therapy. ALRN-6924 may reactivate p53-mediated cell death by targeting both of the natural p53 suppressor proteins, Mouse double minute 2 homolog (MDM2) and MDMX.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Biology Solid Tumors Tumor Inflammation Molecular Biology Lymphoma Cell Biology Metabolic Disease Oncogenes Peptides Hematological Malignancies Proteins P53 Tumor Suppressor Genes Treatment Of A Range Of Cancer Tumor Suppressor
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 7.42 |
| 52 Week Low | 1.01 |
| Average Volume | 107,802 |
| 200-Day Moving Average | 3.22 |
| 50-Day Moving Average | 5.16 |
| 20-Day Moving Average | 4.29 |
| 10-Day Moving Average | 3.80 |
| Average True Range | 0.49 |
| RSI (14) | 38.27 |
| ADX | 17.66 |
| +DI | 18.67 |
| -DI | 22.34 |
| Chandelier Exit (Long, 3 ATRs) | 5.95 |
| Chandelier Exit (Short, 3 ATRs) | 4.75 |
| Upper Bollinger Bands | 5.34 |
| Lower Bollinger Band | 3.24 |
| Percent B (%b) | 0.31 |
| BandWidth | 48.84 |
| MACD Line | -0.41 |
| MACD Signal Line | -0.41 |
| MACD Histogram | -0.0029 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 4.42 | ||||
| Resistance 3 (R3) | 4.40 | 4.20 | 4.34 | ||
| Resistance 2 (R2) | 4.20 | 4.07 | 4.21 | 4.31 | |
| Resistance 1 (R1) | 4.05 | 3.98 | 3.95 | 4.07 | 4.28 |
| Pivot Point | 3.85 | 3.85 | 3.80 | 3.86 | 3.85 |
| Support 1 (S1) | 3.70 | 3.72 | 3.60 | 3.73 | 3.52 |
| Support 2 (S2) | 3.50 | 3.63 | 3.51 | 3.49 | |
| Support 3 (S3) | 3.35 | 3.50 | 3.46 | ||
| Support 4 (S4) | 3.38 |
